Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial

BACKGROUND: Human epidermal growth factor receptor 2 (HER2) targeted therapy combined with endocrine therapy has been recommended as an alternative treatment strategy for patients with hormone receptor (HR)-positive, HER2-positive metastatic breast cancer (MBC). This study aimed to evaluate the role...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Zhe-Yu, Yan, Min, Xiong, Huihua, Ran, Li, Zhong, Jincai, Luo, Ting, Sun, Tao, Xie, Ning, Liu, Liping, Yang, Xiaohong, Xiao, Huawu, Li, Jing, Liu, Binliang, Ouyang, Quchang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294469/
https://www.ncbi.nlm.nih.gov/pubmed/37365596
http://dx.doi.org/10.1186/s12916-023-02943-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294469/
https://www.ncbi.nlm.nih.gov/pubmed/37365596
http://dx.doi.org/10.1186/s12916-023-02943-2

Ejemplares similares